Financial Statements
Prudential’s H1 2024 IFRS profit declines YoY
It dwindled 80.8% to $182m.
AIA Vietnam’s profit dwindles in H1 2024
Revenues from insurance activities fell by 10.4%.
FWD’s net profit halves in H1 2024
All four geographic business segments delivered operating profitability.
Allianz Malaysia’s Q2 2024 earnings show modest growth
The H1 2024 performance of its general segment was offset by its life business.
Generali Vietnam’s net profit plunges in H1 2024
Total assets amounted to $281.5m.
Central Reinsurance Q2 2024 net income surges to $183m
EPS stood at $0.03.
Life Insurance Corporation of India’s Q1 profit up 9.6% YoY
Total premium income for Q1 2024 stood at $1.4b.
Swiss Re targets over $3.6b FY24 net income, bags $2.1b in H1
EPS for the period was $6.97.
Ping An bags $12b net profit in H1 2024
An interim dividend of $0.13 per share in cash was declared.
GIC Re's profit climbs to $12m in Q1 2024
Its assets grew to $2.22b.
IAG’s net profit rises 7.9% in FY 2024
It ended with a final dividend of 17.0 Australian cents per share for the year.
Sumitomo Life net income climbs to $148m in Q1 2024
Gross premiums also surged 31.7% YoY.
HDI Global’s net financial result rises to $76m in H1 2024
Thanks to higher investment volumes and increased interest income.
Suncorp’s full-year earnings climb 12% YoY
Its general insurance segment’s GWP increased by 14%.
Max Life's profit jumps 46% YoY in Q1 FY25
Embedded Value also grew by 30% YoY.
Canopius profits surge 53% in H1 2024
Insurance contract written premiums also climbed 23% YoY.
Thought Leadership Centre
In Association with
Most Read
1. Hong Kong regulator guts insurance referral fees with 50% cap 2. Can China’s $140b motor insurance market survive a 70% loss ratio? 3. PNB MetLife launches dividend fund linked to insurance 4. Taiwan life insurers face rising risk in $32b FX mismatch 5. India set to outpace China, US in premiums by 2030Resource Center
Read Here
Advertise
Sign Up
Awards
Jul
07
Events
Event News
28 March left over 5,300 dead yet coverage was negligible in Myanmar due to under 5% uptake.
